✦ LIBER ✦

New treatments in scleroderma: the rheumatologic perspective

✍ Scribed by A Righi; M Matucci Cerinic

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 85 KB
Volume: 16
Category: Article
ISSN: 0926-9959
DOI: 10.1046/j.1468-3083.2002.00551.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

New treatments in scleroderma: dermatolo

New treatments in scleroderma: dermatologic perspective

✍ S Jablonska; M Blaszczyk 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB

New perspectives in antiemetic treatment

✍ Jørn Herrstedt 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 English ⚖ 447 KB

New perspectives in treatment of glomeru

New perspectives in treatment of glomerulonephritis

✍ Rosanna Coppo; Alessandro Amore 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 612 KB

Frequencies of scleroderma-realted autoa

Frequencies of scleroderma-realted autoantibodies in patients meeting the American Collage of Rheumatology criteria for system sclerosis:replay

✍ John D. Reveille; Frank C. Arnett 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 258 KB 👁 1 views

ChemInform Abstract: New Perspectives fo

ChemInform Abstract: New Perspectives for the Treatment of HIV Infections

✍ E. DE CLERCQ 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 24 KB 👁 2 views

New perspectives in the treatment of HBe

New perspectives in the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B

✍ Thomas Berg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 2 views

BACKGROUND: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term